Plasmid-mediated resistance and virulence mechanisms in the private health sector in KwaZulu-Natal, South Africa: An investigation of methicillin resistant Staphylococcus aureus (MRSA) clinical isolates collected during a three month period  by Amoako, Daniel G. et al.
International Journal of Infectious Diseases 46 (2016) 38–41Short Communication
Plasmid-mediated resistance and virulence mechanisms in the private
health sector in KwaZulu-Natal, South Africa: An investigation of
methicillin resistant Staphylococcus aureus (MRSA) clinical isolates
collected during a three month period
Daniel G. Amoako a, Linda A. Bester b,*, Anou M. Somboro a, Sooraj Baijnath c,
Chetna N. Govind d, Sabiha Y. Essack a
aAntimicrobial Research Unit, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa
bBiomedical Resource Unit, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa
cCatalysis and Peptide Research Unit, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa
d Lancet Laboratories, Durban, KwaZulu-Natal & Honorary Research Fellow, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa
A R T I C L E I N F O
Article history:
Received 22 December 2015
Received in revised form 4 March 2016
Accepted 18 March 2016
Corresponding Editor: Eskild Petersen,
Aarhus, Denmark.
Keywords:
MRSA
plasmids
PCR
PFGE
A B S T R A C T
Objectives: Due to the lack of information on the plasmid content of MRSA strains in South Africa (SA),
this study investigated the resistance and virulence mechanisms of 27 clinical isolates from the private
health care sector over a period of 3 months.
Methods: Plasmids were extracted and the presence of MRSA conﬁrmed by the presence of mecA. The
isolates were subjected to antimicrobial susceptibility testing and molecular characterization of
common resistance encoding genes and frequently encountered virulence factors by PCR using plasmid
DNA as the template. The genetic relatedness between the isolates was determined by pulsed ﬁeld gel
electrophoresis (PFGE).
Results: All isolates were plasmid positive, and displayed ampillicin, ciproﬂoxacin, gentamicin,
rifampicin, tetracycline, erythromycin, and clindamycin resistance. They were all fully susceptible to
daptomycin, linezolid, vancomycin, tigecycline and fusidic acid. Multidrug resistance (MDR) was found
in 74.1% (20/27) of the MRSA isolates. The frequency of the resistance and virulence genes ranged from
100% to 0%. PFGE analysis revealed 10 pulsotypes, designated A–J, which showed correlation with
resistance proﬁle of the isolates in each group. Of note, 85.2% (23/27) of the isolates clustered into six
major PFGE types giving an indication of similar circulating MRSA clones.
Conclusions: This study highlights the genetic diversity and resistance mechanisms in MRSA strains from
the private health sector in SA hence the need for implementing effective infection control programs.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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MRSA is characterized by the presence of mecA that confers
resistance to methicillin. This has far reaching consequences in the
public health, economic and social sectors.1 These strains also harbor
mobile genetic elements (MGEs), including plasmids, pathogenicity
islands, transposons, integrons and prophages, which comprise
15–25% of the genome. An understanding of these MGEs will
broaden our knowledge on the genetic determinants of antibiotic* Corresponding author. Private Bag X54001, University of KwaZulu-Natal,
Durban, 4000.
E-mail address: besterl@ukzn.ac.za (L.A. Bester).
http://dx.doi.org/10.1016/j.ijid.2016.03.019
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).resistance (AR).2 Although research has been conducted on MRSA in
SA, information on the plasmid content is largely unknown, a study
of this nature is important understanding AR patterns, comparing
the plasmid proﬁles will help in effective infection control. The aim
of this study was to ascertain the genetic relatedness, and
characterize the plasmid-encoded antibiotic resistance and viru-
lence proﬁle of clinical MRSA isolates collected obtained from a
private laboratory in Durban, SA over a three month period.
2. Methods
A total of 27 consecutive non-repetitive MRSA isolates were
obtained from June to August 2015, from a pathology laboratory
that caters for the private healthcare sector. The isolates wereciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Clinical data, minimum inhibitory concentrations (MIC), and results of PCR for 27 MRSA isolates
Isolate No. Clinical data MIC (mg/l)b PCR
Hos.
codec
Sourcea Ward
typea
Sex Agea AP CP GT ET RF TT CM DP VM LZ FA TG mecA blaZ ermC aac-
aph
tetK hla hld eta lukS/
F-PV
B11970 1 Blood Neo ICU F NB >512 0.5 32 8 0.25 2 0.25 1 1 2 0.25 0.25 + + + + - + + - -
P10781 15 Nasal OPD M 86 >512 256 64 32 512 256 0.25 0.5 1 2 0.25 0.25 + + + + - + + - -
P10747 2 CVP ICU F 66 >512 4 >64 64 512 128 0.25 0.5 0.5 1 0.25 0.25 + + + + - + + - -
S37938 - - - - - >512 256 16 32 256 64 2 0.5 1 2 0.25 0.25 + + + + - + + - -
S18155 3 ETT ICU F 76 >512 256 64 64 256 128 0.25 0.25 0.5 2 0.25 0.25 + + - + - + - - -
B13178 5 Blood LW F 26 >512 256 >64 64 512 128 0.25 0.5 1 2 0.25 0.25 + + + + - + + - -
440260 - - - - - >512 >512 >64 64 256 128 0.25 0.5 1 2 0.25 0.25 + + + + - + + - -
S18970 - - - - - >512 256 64 32 512 64 0.25 0.5 0.5 2 0.25 0.25 + + - + - + + - -
P11520 6 Pus OPD M 62 512 >512 0.25 0.5 0.25 0.25 0.25 0.5 1 2 0.25 0.25 + + - - - + + - -
T5683 7 Nasal OPD F 43 >512 8 0.5 0.5 256 32 0.25 0.5 1 1 0.25 0.25 + + - - - + + - -
B15227 1 Blood Neo ICU F NB >512 4 64 8 0.25 0.25 0.25 1 1 1 0.25 0.25 + + + + - + + - -
P13563 - - - M 49 >512 128 >64 0.5 128 16 0.25 0.5 1 2 0.25 0.25 + + - + - + + - -
S22589 4 Sputum ICU M 49 >512 128 >64 0.5 128 64 0.25 1 1 2 0.25 0.25 + + - + - + + - -
B15612 8 Blood ICU M 46 >512 128 >64 16 512 256 0.25 1 1 2 0.25 0.25 + + - + - + - - -
B15810 5 Pus Surgical M 41 >512 256 32 16 128 64 0.25 0.5 1 2 0.5 0.25 + + + + - + + - -
B15583 1 Blood ICU F 37 >512 16 >64 2 64 2 0.25 0.5 1 2 0.25 0.25 + + - + - + + - -
S24463 10 ETT ICU F 59 512 1 32 1 0.25 0.25 1 0.5 0.5 2 0.25 0.25 + + + + - + + - -
P15045 1 Wound Surgical F 47 >512 64 64 16 256 64 0.25 0.25 0.25 2 0.25 0.25 + + - + - + + - -
P15028 10 Eye Nursery F NB 512 4 16 0.5 0.5 0.25 0.25 0.25 1 2 0.25 0.25 + + - + - - + - -
P14890 11 Wound ICU F 41 512 256 64 0.5 256 128 0.25 0.5 1 2 0.25 0.25 + + - + - + + - -
P15558 1 CVP Medical F 94 512 >512 0.12 1 256 0.25 >512 0.5 0.5 1 0.25 0.25 + + + + - + + - -
P15469 12 Humerus General F 68 128 64 1 0.5 0.25 0.5 0.25 0.25 0.5 2 0.25 0.25 + + - + - + + - -
P15490 13 Bone General M 63 >512 128 32 16 128 64 0.25 0.25 0.5 2 0.25 0.25 + + + + - + + - -
P15742 6 cheek Trauma M 29 256 0.5 0.5 16 0.25 64 0.25 0.25 0.5 2 0.25 0.25 + + + + - + + - -
P15825 14 Buttock Paediatri M 5 512 1 0.5 0.5 0.25 0.25 0.25 0.25 1 2 0.25 0.25 + + - + - + + - -
P15793 2 Head Surgical M 10 512 256 64 32 256 32 0.25 0.5 0.5 2 0.25 0.25 + + + + - + + - -
T8060 - - - - - 512 4 4 16 128 64 0.25 0.5 0.5 2 0.25 0.25 + + - + - + + - -
a ETT, Endotracheal tube; CVP, Central venous catheter; ICU, Intensive/High care unit; LW, Labour ward: OPD, outpatient department, NB, Newborn (day 0), -, No information.
b AP, ampicillin; CP, ciproﬂoxacin; GT, gentamicin; ET, erythromycin; RF, rifampicin; TT, tetracycline; CM, clindamycin; DP, daptomycin; VM, vancomycin; LZ, linezolid; FA, fusidic acid; TG, tigecycline.
c The numbers 1–15 indicates codes of the hospital centers where the MRSA isolates were collected.
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D.G. Amoako et al. / International Journal of Infectious Diseases 46 (2016) 38–4140identiﬁed using Vitek 2 (bioMerieux, Durham, NC, USA) and
conﬁrmed by matrix assisted laser desorption ionization time of
ﬂight mass spectrometry (MALDI-TOF/MS). The cefoxitin disc
diffusion (CDD) test was used to identify putative MRSA, which
was then conﬁrmed by PCR detection of mecA. The MIC was
determined for 12 antibiotics by the broth microdilution method.
The Clinical and Laboratory Standards Institute (CLSI) Guideline3was
used for interpreting the results, and Staphylococcus aureus ATCC
29213 was used as the control. Isolates resistant to b-lactams, and at
least three classes of antibiotics, were deﬁned as multidrug resistant
(MDR). A plasmid DNA extraction kit (GeneJET Plasmid Miniprep kit,
Thermoscentiﬁc) was used to purify the plasmid DNA from all
27 MRSA strains, according to the manufacturer’s instructions. The
presence of resistance genes conferring resistance to ampicillin-
penicillin (blaZ), aminoglycoside (aac (60)–aph (200)), macrolide-
lincosamide-streptogramins B [MLSB] (ermC) and tetracycline (tetK)
were determined using PCR. The virulence determinants encoding
the bio-component Panton-Valentine leukocidin (LukS/F-PV gene),
exfoliative toxin (eta), alpha and delta hemolysin genes (hla and hld)
were also ascertained by PCR. PFGE was used to predict the genetic
relatedness of the MRSA isolates. Clusters were deﬁned using the
criterion of a difference of 6 bands, as described by Tenover et al4,
and a similarity cut-off of 70.0%.Figure 1. PFGE SmaI genotypic types generated from clinical MRSA isolates from private s
reference control strain. The R and S indicate resistance or susceptibility for ciproﬂoxacin
A–J shows the main pulsotype and subtype of each isolate. The numbers 1–15 indicat3. Results and discussion
The demographic data and resistance patterns of the isolates and
MICs are summarized in Tables 1 and S1. Ampicillin showed no
activity against MRSA isolates, while 85.2% (23/27) were resistant
to ciproﬂoxacin, 74.1% (20/27) to gentamicin, 70.4% (19/27) to
rifampicin, 66.7% (18/27) to tetracycline, 63.0% (17/27) to erythro-
mycin, and 11.1% (3/27) to clindamycin. Multidrug resistance (MDR)
was determined in 74.1% (20/27) of the MRSA isolates. Resistance
rates in this study varied compared to those seen in another KZN
study on 61 conﬁrmed MRSA isolates by Shittu et al5, particularly for
gentamicin (74.1% vs. 96.7%), rifampicin (70.4% vs. 73.8%), tetracy-
cline (66.7% vs. 90.2%) and erythromycin (63.0% v. 82.0%). Resistance
to clindamycin of 11.1% was also much lower in this investigation
than the rates of 82%5 and 62.5%6 reported in other studies
conducted on MRSA isolates in KZN and SA. Only the ciproﬂoxacin
resistance rate in our study was notably higher (85.2% v. 18%5), with
its resistance on MRSA isolates in SA having been reported to 69.7%
and 88.7% in the private sector.6Multidrug resistance rate was lower
(74.1% vs. 87%) than those reported by Shittu et al5 but similar to a
study by Heysell et al7 in KZN with a rate of 79% on 19 clinical MRSA.
All MRSA isolates were susceptible to daptomycin, vancomycin,
linezolid, fusidic acid and tigecycline, ampillicin. The susceptibilityector in KZN. Pretested Salmonella serotype Braenderup strain H9812 was used as the
, gentamicin, erythromycin, tetracycline and rifampicin respectively. The alphabets
es codes of the hospital centers where the MRSA isolates were collected.
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conducted on MRSA in South Africa5,6which were totally susceptible
to daptomycin, vancomycin, linezolid, fusidic acid and tigecycline.
The susceptibility of MRSA to these antibiotics observed in this study
conﬁrms their use as treatment options for infections in SA.
The structural component of mecA encodes the penicillin-
binding protein 2a (PBP2a) that establishes resistance to methicil-
lin, other semisynthetic penicillinase-resistant beta-lactams that
are frequently co-carried with genes conferring resistance to
aminoglycosides, macrolide-lincosamide-streptogramin B [MLSB]
and spectinomycin.8 All the isolated plasmids of the MRSA isolates
contained the mecA and blaZ resistance genes, showing the
correlation between MICs and the presence of genes encoding
resistance against beta-lactams. The gentamicin resistance gene
aac (60)–aph (200) was identiﬁed in 25 (92.6%) of the isolates, which
varied from the phenotypic resistance proﬁle of 74.1%, indicating
that gene carriage does not necessarily translate into the resistance
phenotype. The ermC gene responsible for macrolide-lincosamide-
streptogramins B [MLSB] resistance was ampliﬁed in 48.2% (13/27)
of the MRSA isolates, while it was not found in those that were
susceptible to both erythromycin and clindamycin. The 23.5% (4/
17) with phenotypic resistance to MLSB that did not contain the
ermC gene indicates the occurrence of other resistance mechanism,
ermA, ermB and msrA, which was not investigated in this study but
have been previously reported.9 This conﬁrms that the incidence of
MLSB phenotypes and genotypes vary according to country,
patterns of infections and drug use.9 Although there was high
tetracycline resistance, the tetK gene was not detected, indicating
that this may be due to different mechanisms and not mediated by
active drug efﬂux, as tetK resistance has so far not been reported in
clinical MRSA studies in South Africa.
The prevalence of virulence factors in all isolated plasmids
showed a similar trend, with the hla and hld being the most abundant
genes, with frequencies of 96.3% (26/27) and 92.6% (25/27)
respectively. Comparatively, this was similar to other studies
conducted from Uganda10 and United States,11 with either hla being
more frequent than the hld genes, or both showing 100% co-
dominance. The prevalence rate of eta in our study was 0%, however,
the prevalence of eta differed among studies, which could be
associated with a variety of geographical and health conditions.12
LukS/F-PV was not detected in any of the 27 clinical MRSA isolates,
which was comparable to a study conducted in South Africa on
320 clinical MRSA isolates with only one positive LuKS/F-PV gene
being detected.13
The PFGE proﬁles and the dendrogram of the MRSA isolates are
shown in Figure 1. PFGE analysis grouped the 27 isolates into
10 pulsotypes designated A-J, displaying 70.0% similarity, and
correlating with their resistance proﬁle and the genetic determi-
nants tested in this study (Fig. 1). Of note, 85.2% of the isolates were
clustered into six major PFGE types: pulsotypes F (8/27 strains;
29.6%), G (5/27; 18.5%), C, I (3/27; 11.1%) and A, H (2/27; 7.4%). Pulse
types B, D, E and J were each represented by single isolates. Although
the sample size was too small to show a deﬁnite correlation, the
assertion of similar circulating clones in the province was supported
by our study, as the PFGE analysis revealed some form of association
between pulsotypes and the centers of sample collection. Centers
1 and 10 were found to contain pulsotypes C and H, while identical
pulsotypes F and G were spread across nine of the 15 centers,
intimating the possibility of similar clones of MRSA within the health
care centers in the province as predicted by Shittu et al14 and
Moodley et al13 in their study in KZN and SA respectively.
To the best of our knowledge this is the ﬁrst study characterizing
the plasmid-mediated resistance and virulence genes of clinical
MRSA isolates in the private sector in Durban. The study provides a
private sector perspective of antibotic resistance patterns andgenetic relatedness of MRSA highlighting the need for implementing
efﬁcient and effective infection control programs.
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